Our practice has been conducting clinical trials for more than 20 years. These studies have predominantly been phase 3 and phase 4 trials. During the 80s, the practice’s initial clinical studies entailed the evaluation and comparison of the H2 blocker medication to the then newly developed proton pump inhibitors in the treatment of erosive esophagitis and peptic ulcer disease. Subsequently, during the ensuing years, we have participated in the clinical trials of almost all of the current proton pump inhibitors. We have most recently completed a study evaluating the efficacy of a newly developed sustained release “AcipHex”.
Additionally, our practice has participated in the initial clinical trials of the anti-tumor necrosis factor monoclonal antibody, Adalimumab, for the treatment of Crohn’s disease (the CHARM, GAIN and TREATtrials).
Other investigations of clinical trials have included medications treating multiple medical conditions and illnesses, including but not limited to, ulcerative colitis, irritable bowel syndrome, colon cancer prevention, colonic polyp prevention and hepatitis C.